Author:
Arrieta Oscar,Villarreal-Garza Cynthia,Vizcaíno Gloria,Pineda Benjamín,Hernández-Pedro Norma,Guevara-Salazar Patricia,Wegman-Ostrosky Talia,Villanueva-Rodríguez Geraldine,Gamboa-Domínguez Armando
Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. Jemal ABF, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. Duchnowska R, Jassem J, Goswami CP, Dundar M, Gokmen-Polar Y, Li L, et al. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients. J Neuro-Oncol. 2015. doi: 10.1007/s11060-014-1704-y .
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92. doi: 10.1056/NEJM200103153441101 .
4. Cianfrocca M. Overcoming recurrence risk: extended adjuvant endocrine therapy. Clin Breast Cancer. 2008;8(6):493–500. doi: 10.3816/CBC.2008.n.059 .
5. de Paepe B, Verstraeten VL, de Potter CR, Vakaet LA, Bullock GR. Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. Histochem Cell Biol. 2001;116(3):247–54. doi: 10.1007/s004180100313 .
Cited by
55 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献